The latest update is out from Pharma Mar SA ( (ES:PHM) ).
Pharma Mar SA announced the suspension of its liquidity contract with JB Capital Markets, effective February 28, 2025, following the completion of a share buyback program and the initiation of a new one. This move is part of the company’s ongoing efforts to manage its share liquidity and optimize shareholder value, reflecting strategic financial maneuvers that may impact its market positioning and investor relations.
More about Pharma Mar SA
Pharma Mar SA operates in the pharmaceutical industry, focusing on the development and commercialization of marine-derived drugs. The company is known for its innovative approach to cancer treatment and other therapeutic areas, leveraging unique compounds found in marine organisms.
YTD Price Performance: 4.76%
Average Trading Volume: 1,304
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.55B
Find detailed analytics on PHM stock on TipRanks’ Stock Analysis page.